Bank of America has revised its price target for NeoGenomics (NEO, Financial), reducing it from $16 to $12 while maintaining a Neutral rating on the stock. The adjustment comes as the sentiment towards the Life Sciences and Diagnostic Tools sector, as well as Contract Research Organizations, is notably pessimistic ahead of upcoming earnings reports.
These companies are currently experiencing significant pressures due to various policy shifts initiated during the Trump Administration. Key challenges include reductions in the National Institutes of Health budget and global tariffs, alongside broader macroeconomic concerns. In particular, the evolving economic situation in China is adding to the sector's uncertainties.
This cautious outlook reflects the intersection of these external factors impacting the industry, influencing investor sentiment and projections for the near future.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for NeoGenomics Inc (NEO, Financial) is $18.67 with a high estimate of $26.00 and a low estimate of $15.00. The average target implies an upside of 89.51% from the current price of $9.85. More detailed estimate data can be found on the NeoGenomics Inc (NEO) Forecast page.
Based on the consensus recommendation from 15 brokerage firms, NeoGenomics Inc's (NEO, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for NeoGenomics Inc (NEO, Financial) in one year is $18.84, suggesting a upside of 91.27% from the current price of $9.85. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the NeoGenomics Inc (NEO) Summary page.
